A New P-Heterocyclic Family: A Variety of Six-Membered and Bridged P-Heterocycles with 1-Benzyl Substituent

Tibor Novák,¹ János Deme,² Krisztina Ludányi,^{3,4} and György Keglevich²

¹*Research Group of the Hungarian Academy of Sciences at the Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, 1521 Budapest, Hungary.*

²*Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, 1521 Budapest, Hungary.*

³*Department of Pharmaceutics, Faculty of Pharmacy, Semmelweis University, 1092 Budapest, Hungary*

⁴*Chemical Research Center, Hungarian Academy of Sciences, 1525 Budapest, Hungary*

Received 16 February 2007; revised 6 April 2007

ABSTRACT: *The ring enlargement of 1-benzyl-2,5 dihydro-1H-phosphole oxide (***1***) via the corresponding 2-phosphabicyclo[3.1.0]hexane 2-oxide (***2***) afforded, depending on the conditions, the double bond isomers (***A** *and* **B***) of 1,2-dihydrophosphinine oxide* **4** *or that of 3-substituted 1,2,3,6-tetrahydrophosphinine oxides* **5** *and* **6***. Dihydrophosphinine oxides (***4***) were suitable starting materials for 1,2,3,4,5,6 hexahydrophosphinine oxide* **7** *and 1,2,3,6 tetrahydrophosphinine oxide* **8** *obtained by reductive approaches and for the double bond isomers (***A** *and* **B***) of 2-phosphabicyclo[2.2.2]octadiene 2-oxide* **9** *and phosphabicyclooctene oxide* **10** *prepared in Diels– Alder cycloaddition. Precursor* **9** *was utilized in the fragmentation-related phosphorylation of alcohols.*

Contract grant sponsor: Bolyai Fellowship (for TN).

c 2008 Wiley Periodicals, Inc.

^C 2008 Wiley Periodicals, Inc. Heteroatom Chem 19:28–34, 2008; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hc.20363

INTRODUCTION

P-Heterocycles have attracted much attention recently and represent a growing field mainly from the point of view of their use as Pligands [1]. In our laboratory, a ring enlargement method was developed making available a variety of 2-phosphabicyclo[3.1.0]hexane oxides, 1,2- and 1,4-dihydrophosphinine oxides, different 1,2,3,6-tetrahydrophosphinine oxides, 1,2,3,4,5,6 hexahydrophosphinine oxides, phosphepine oxides, and bridged phosphabicyclo[2.2.2]octene derivatives [2–6], the latter being precursors of lowcoordinate fragments useful in the phosphorylation of nucleophiles [6]. The intermediates of the above P-heterocycles are the suitably substituted 2,5-dihydro-1*H*-phosphole 1-oxides available easily. The 1-benzyl-P-heterocycles form a relatively less studied group; only simple derivatives,

The paper is dedicated to Professor Dr. Csaba Szántay on the occasion of his 80th birthday.

Correspondence to: G. Keglevich; e-mail: keglevich@mail. bme.hu.

Contract grant sponsor: Hungarian Scientific Research Fund (OTKA).

Contract grant number: T067679.

Me

Me

Bn

4А

4B

SCHEME 1

such as the corresponding 1H-phosphole [7], 2,5-dihydro- and 2,3,4,5-tetrahydro-1*H*-phosphole oxides [8,9], as well as some other species including 7-phosphanorbornene 7-oxides [10] have been described. In this paper, the 1-benzyl derivatives of a variety of six-membered P-heterocycles, mainly phosphinines, as well as bridged P-heterocycles, such as phosphabicyclooctenes, are discussed.

RESULTS AND DISCUSSION

1-Benzyl-2,5-dihydro-1*H*-phosphole 1-oxide **1** was subjected to dichlorocyclopropanation reaction using dichlorocarbene generated from chloroform by aqueous sodium hydroxide under phase transfer catalytic conditions, as described for other cases [2]. 2-Phosphabicyclo[3.1.0]hexane 3-oxide **2** was obtained as a 3:1 mixture of two (**A** and **B**) diastereomers (Scheme 1). The stereochemical assignment was justified by earlier arguments [11]. The isomeric mixture of phosphabicyclohexane oxide (**2**) was converted to the corresponding sulfide **3** with phosphorus pentasulfide (Scheme 1).

The second step of the ring enlargement involved opening of the dichlorocyclopropane ring, which was carried out thermally to afford a 3:1 mixture of the double bond isomers (**A** and **B**) of dihydrophosphinine oxide **4** (Scheme 2) or was done under solvolytic conditions applying silver nitrate and methanol or water to give a mixture of the double bond isomers (**A** and **B**) of 3-methoxy- or 3 hydroxy-1,2,3,6-tetrahydrophosphinine oxides **5** and **6**, respectively (Scheme 3). The double bond isomer (**A** and **B**) of compounds **5** and **6** consisted of diastereomers.

In the next part of our project, 1,2 dihydrophosphinine oxide (**4**) was utilized in the synthesis of other P-heterocycles. Catalytic hydrogenation of the isomeric mixture of **4** furnished 1,2,3,4,5,6-hexahydrophosphinine oxide **7**

 $2A$

 $2B$

135°C

- HCI

as a mixture of two diastereomers (Scheme 4). It was found earlier that the hydrogenation of 2-phosphabicyclo[3.1.0]hexane oxides at somewhat more forcing conditions may also lead to the corresponding hexahydrophosphinine oxides [12]. However, transformation of the isomeric mixture of phospabicyclohexane **2** to **7** was not too efficient. The reason for this experience may stem the sensitivity of the P-benzyl moiety under hydrogenation.

A selective reduction of the electron-poor double bond of the isomers **A** and **B** of dihydrophosphinine oxide **4** was achieved by dimethylsulfide borane. The reduction of isomer **4A** was found to be more efficient than that of **4B**. Hence, the 3:1 isomeric ratio of starting isomers **4A** and **4B** was shifted to 9:1 in regard to products **8A** and **8B** (Scheme 5).

Finally, 1,2-dihydrophosphinine oxides **4A** and **4B** were used as dienes in the Diels–Alder reaction. In cycloaddition with dimethyl acetylenedicarboxylate (DMAD) and *N*-phenylmaleimide (NPMI), the double bond isomers (**A** and **B**) of 2 phosphabicyclo[2.2.2]octadiene **9** and phosphabicyclooctene **10** were formed, respectively (Scheme 6). Isomers **9A** and **9B** consisted of two diasteromers.

SCHEME 3

SCHEME 4

The bridged P-heterocycles **9** and **10** were tested in the UV light mediated fragmentation-related phosphorylation of simple alcohols. Irradiation of the acetonitrile solution of the isomeric mixture of phosphabicyclooctadiene **9** in the presence of methanol, ethanol, propanol, and butanol at 254 nm led to phosphinates **11a–d** (Scheme 7). Surprisingly, precursor **10** was not found to be useful in similar phosphorylations due to intensive decomposition in UV light. In the presence of methanol, the photolysis of **10** led to by products, revealing 31P NMR shifts at

SCHEME 5

39.2 and 40.5 ppm that could not be identified yet. The expected phosphinate (**11a**) was formed only in small proportion (less than 5%).

It is recalled that in the case of phenyl substitution, the use of the corresponding dihydrophosphinine oxide–NPMI cycloadduct was more appropriate in photoinduced phosphorylation than that of the DMAD cycloadduct [13].

P-Heterocycles **2–8**, mostly as isomeric pairs, were characterized by 31P, 13C, and 1H NMR, as well as mass spectral data. At the same time, the spectral parameters of precursors **9** and **10** were compared with those of authentic samples prepared in the meantime under microwave conditions and to be published elsewhere [14].

In summary, new benzyl-substituted P-heterocycles including 2-phosphabicyclo[3.1.0]hexane oxide and sulfide, 1,2-dihydro-, 1,2,3,6.tetrahydroand 1,2,3,4,5,6-hexahydrophosphinine oxides, as well as 2-phosphabicyclo[2.2.2]octadiene derivatives were obtained and characterized. One of the bridged P-heterocycles proved to be an efficient reagent in the photoinduced phosphorylation of alcohols.

EXPERIMENTAL

The ${}^{31}P$, ${}^{13}C$, and ${}^{1}H$ NMR spectra were taken on a Bruker DRX-500 spectrometer operating at 202.4, 125.7, and 500 MHz, respectively. Chemical shifts are downfield relative to 85% H₃PO₄ and TMS. The couplings are given in hertz. Mass spectrometry was performed on a ZAB-2SEQ instrument. Isomeric ratios were determined on the basis of relative ³¹P NMR intensities. Photolyses were conducted in a photochemical reactor equipped with a quartz, water-cooled immersion well with a high-pressure mercury lamp (125 W). The starting 1-benzyl-3-

SCHEME 6

SCHEME 7

methyl-2,5-dihydro-1*H*-phosphole oxide (**1**) was prepared as described earlier [15].

3-Benzyl-6,6-dichloro-1-methyl-3-phosphabicyclo[3.1.0]hexane 3-oxide **2**

To 21.4 g (100 mmol) of dihydrophosphole oxide **1** and 5.0 g (22.0 mmol) of triethylbenzylammonium chloride (TEBAC) in 200 mL of chloroform, 125 g (3.13 mol) of sodium hydroxide in 125 mL of water was added dropwise and the mixture was stirred until it cooled down to room temperature. After filtration and separation, the organic phase was made up to its original volume and 1.7 g (7.5 mmol) of TEBAC was added. The reaction mixture was treated with three more times with aqueous sodium hydroxide (125 g/125 mL, 150 g/150 mL, 150 g/150 mL NaOH/H₂O, respectively) as mentioned above. The solution obtained after filtration and separation was concentrated in vacuo, and the residue so obtained was purified by chromatography (2% methanol in chloroform, silica gel) to give 22 g (75%) of a 3:1 mixture of **2A** and **2B**; HRMS, $[M + H]_{\text{found}}^+ = 289.0310$, $C_{13}H_{16}Cl_2$ OP requires 289.0316.

2A. ³¹P NMR (CDCl₃) δ : 85.6; ¹³C NMR (CDCl₃) δ: 21.0 $(J = 6.0, \text{ CH}_3)$, 28.5 $(J = 64.6, \text{ C}4)$, 34.3

 $(J = 65.0, \text{ CPh})$, 35.3 $(J = 7.5, \text{ C}_1)$, 36.1 $(J = 6.0, \text{ C}_5)$, 36.9 ($J = 55.1$, C2), 71.7 ($J = 8.7$, C₆), 126.6 ($J = 3.0$, C_4), 128.4 (*J* = 2.5, C_3), 128.9 (*J* = 5.3, C_2), 131.3 $(J = 8.1, C_{1'})$, C_{ipso} , C_{ortho} , C_{meta} , and C_{para} are marked by C_{1'}, C_{2'}, C_{3'} and C_{4'}, respectively; ¹H NMR (CDCl₃) δ : 1.63 (s, 3H, CH₃), 2.03–2.22 (m, 1H, C₅-H), 2.25– 2.45 (m, 2H, CH₂), 2.52–2.80 (m, 2H, CH₂), 3.31 (d, 2H, $J = 12.8$, CH₂Ph), 7.15–7.45 (m, 5H, Ar).

2B. ³¹P NMR (CDCl₃) δ : 82.4; ¹³C NMR (CDCl₃) δ : 20.3 ($J = 7.0$, CH₃), 27.0 ($J = 63.6$, C₄), 33.1 ($J = 63.8$, CPh), 35.4 $(J = 7.3, C_1)$, 36.0 $(J = 6.5, C_5)$, 37.0 $(J = 54.2, C2)$, 71.8 $(J = 11.6, C_6)$, 126.8 $(J = 2.9, C_4)$, $128.5 (J = 2.4, C_3)$, $129.0 (J = 5.1, C_2)$, $130.7 (J = 7.2,$ $C_{1'}$); ¹H NMR (CDCl₃) δ: 1.50 (s, 3H, CH₃).

3-Benzyl-6,6-dichloro-1-methyl-3-phosphabicyclo[3.1.0]hexane 3-sulfide **3**

To 0.30 g (1.0 mmol) of phosphabicyclohexane oxide **2** consisting of isomers **A** (75%) and **B** (25%) in 5 mL of degassed benzene, 0.16 g (0.7 mmol) of P_2S_5 was added and the mixture was refluxed for 20 h under nitrogen. The suspension was filtered, the solvent of the filtrate evaporated, and the residue purified by column chromatography (3% methanol in chloroform, silica gel) to give 0.29 g (91%) of **3** as a 4:1 mixture of diastereoisomers **A** and **B**. HRMS, $[M + H]_{\text{found}}^+ = 305.0069$, $C_{13}H_{15}C_{2}SP$ requires 305.0087.

3A. ³¹P NMR (CDCl₃) δ : 88.4; ¹³C NMR (CDCl₃) δ : 21.0 (*J* = 6.5, CH3), 33.3 (*J* = 51.7, C4), 37.0 (*J* = 7.3, C₁), 38.0 ($J = 6.2$, C₅), 38.5 ($J = 51.2$, CPh), 41.0 $(J = 40.0, C2)$, 72.5 $(J = 11.9, C_6)$, 127.9 $(J = 3.4, C_4)$, $129.0 (J = 2.9, C_3)$, $129.9 (J = 5.1, C_2)$, $131.4 (J = 7.9, C_3)$ $C_{1'}$); ¹H NMR (CDCl₃) δ: 1.35 (s, 3H, CH₃), 1.75 (ddd,

1H, $J_1 = 18.1$, $J_2 = 8.3$, $J_3 = 2.2$, CH₂), 1.23 (ddd, 1H, $J_1 = 16.0, J_2 = 7.6, J_3 = 2.0, CH_2$, 2.29–2.43 (m, 2H, CH_2 and CH), 2.65–2.75 (m, 1H, CH₂), 3.36 (dt, 2H, $J = 28.8$, 13.5, CH₂Ph), 7.22–7.40 (m, 5H, Ar). **3B.** ³¹P NMR (CDCl₃) δ : 88.6.

1-Benzyl-4-chloro-3-methyl-1,2-dihydrophosphinine 1-oxide **4**

A 0.50 g (1.73 mmol) sample of phosphabicyclohexane oxide **2** consisting of isomers **A** (75%) and **B** (25%) was heated at 135◦ C in a vial for 4 min (the evolution of hydrochloride acid started after 1 min). The crude product was purified by column chromatography (2% methanol in chloroform, silica gel) to give 0.38 g (87%) of dihydrophosphinine 1-oxide **4** as a 3:1 mixture of **4A** and **4B**. MS, 253 (100, $[M+H]^+$), 154 (68), 136 (67), 91 (93), 69 (82); HRMS, $[M + H]_{\text{found}}^+ = 253.0555$, $C_{13}H_{15}CIOP$ requires 253.0549.

4A. ³¹P NMR (CDCl₃) δ : 23.9; ¹³C NMR (CDCl₃) δ : 22.2 ($J = 8.4$, CH₃), 31.6 ($J = 69.3$, C₂), 37.0 ($J = 68.1$, C7), 118.0 ($J = 89.9$, C₆), 122.7 ($J = 18.8$, C₃), 126.0 $(J = 3.3, C_4)$, 126.1 $(J = 3.3, C_4)$, 127.8 $(J = 2.8, C_3)$, $128.6 (J = 5.3, C_2)$, $130.0 (J = 7.9, C_1)$, $142.4 (J = 1.2,$ C₅); ¹H NMR (CDCl₃) δ: 1.96 (s, 3H, CH₃), 2.58 (dd, 1H, $J = 18.6$, 11.3, CH₂), 2.76 (t, 1H, $J = 19.5$, CH₂), 3.26 (dd, 2H, $J = 15.5$, 4.2, CH₂Ph), 6.08 (t, 1H, $J = 12.7$, C₆H), 6.67 (dd, 1H, $J = 34.1$, 12.9, C₅H), 7.22–7.38 (m, 5H, Ar).

4B. ³¹P NMR (CDCl₃) δ: 22.5; ¹³C NMR (CDCl₃) δ: 23.6 ($J = 12.5$, CH₃), 30.2 ($J = 68.0$, C₂), 36.6 $(J = 68.4, \text{CPh})$, 117.5 $(J = 93.6, \text{C}_6)$, 122.2 $(J = 10.2, \text{C}$ (C_3) , 125.8 ($J = 3.1$, C_4), 126.1 ($J = 3.3$, $C_{4'}$), 127.8 $(J = 2.8, C_{3'})$, 128.7 $(J = 5.3, C_{2'})$, 130.2 $(J = 8.0, C_{1'})$, 143.7 ($J = 1.6$, C₅); ¹H NMR (CDCl₃) δ : 2.12 (s, 3H, $CH₃$).

5- and 3-Methyl-1-benzyl-4-chloro-3-methoxy-1,2,3,6-tetrahydrophosphinine 1-oxide **5**

A solution of 0.40 g (1.38 mmol) of phosphabicyclohexane oxide **2** consisting of isomers **A** (75%) and **B** (25%) and 4.2 g (25.0 mmol) of silver nitrate in 15 mL of methanol was refluxed for 24 h. After filtration, the mixture was extracted with chloroform and the organic phase was dried over sodium sulfate and concentrated. The crude product was purified by column chromatography (3% methanol in chloroform, silica gel) to give 0.29 g (70%) of compound **5** as a 40:28:21:10 mixture of four isomers with a purity of 95%. A further refinement by chromatography led to a 1:1.1:1.2:1 mixture of the isomers. MS, 285 (88, $[M+H]^+$), 253 (64), 137 (100); HRMS, $[M+H]^+_{\text{found}}$ $= 285.0799$, C₁₄H₁₉ClO₂P requires 285.0811.

5-1^A.* ³¹P NMR (CDCl₃) δ : 37.8; ¹³C NMR (CDCl₃) δ: 22.5 ($J = 8.5$, CH₃), 29.8 ($J = 63.2$, C₆),^a 33.1 $(J = 59.5, C_2)$,^a 36.4 $(J = 63.0, CPh)$,^b 55.8 (CH₃O), 78.5 $(J = 4.2, C_3)$, 126.7 (C_4) , 128.6 $(J = 5.3, C_5)$, 128.4 (C_3) ,^d 129.0 $(J = 5.1, C_2)$,^e 130.6 $(J = 11.1,$ $C_{1'}$),^f 137.3 (*J* = 11.4, C₄); ¹H NMR (CDCl₃) δ: 1.88 $(s, 3H, CH₃), 2.00-2.72$ (m, 4H, P(CH₂)2), 3.21 (d, 2H, $J = 15.0$, CH₂Ph), 3.43 (s, 3H, OCH₃),^g 4.00–4.30 (m, 1H, CH), 7.10–7.42 (m, 5H, Ar).

5-2^A. ³¹P NMR (CDCl₃) δ : 35.0; ¹³C NMR (CDCl₃) δ : 22.9 (*J* = 8.5, CH₃), 28.9 (*J* = 62.5, C₆),^h 31.3 $(J = 62.0, C_2)$, 37.5 $(J = 62.8, CPh)$, 57.3 (CH_3O) , 79.1 ($J = 5.3$, C₃), 126.7 (C_{4'}),^c 128.4 (C_{3'}),^d 129.4 $(J = 5.1, C_{2'})$, $\binom{0}{1}$ 131.0 $(J = 8.5, C_{1'}$ ¹H NMR (CDCl₃) δ : 1.94 (s, 3H, CH₃), 2.00–2.72 (m, 4H, $P(CH_2)$, 3.21 (d, 2H, $J = 15.0$, CH₂Ph), 3.37 (s, 3H, OCH₃),^g 4.00–4.30 (m, 1H, CH), 7.10–7.42 (m, 5H, Ar).

5-3^B. ³¹P NMR (CDCl₃) δ : 35.8; ¹³C NMR (CDCl₃) δ: 25.8 $(J = 63.5, C_6)$, 26.9 $(J = 5.6, CH_3)$, 35.7 $(J = 60.7, C_2)$, 36.4 $(J = 63.5, CPh)^b$ 50.4 (CH_3O) , 77.0 $(J = 3.1, C_3)$, 122.4 $(J = 6.2, C_5)$, 126.7 (C_4) , $127.9 (J = 10.9, C_4), 128.4 (C_{3'})^d 129.1 (J = 4.9, C_{2'})^e$ 130.7 $(J = 8.1, C_{1})^{\frac{t}{r}}$, ¹H NMR (CDCl₃) δ : 1.52 (s, 3H, CH₃), 2.00–2.72 (m, 4H, P(CH₂)₂), 3.21 (d, 2H, $J = 15.0$, CH₂Ph), 3.22 (s, 3H, OCH₃),^g 6.06 (bdt, 1H, $J^1 = 23.0, J^2 = 10.0, \text{CH} = 10, 7.10 - 7.42 \text{ (m, 5H, Ar)}.$

5-4^B. ³¹P NMR (CDCl₃) δ : **36.1**; ¹³C NMR (CDCl₃) δ: 25.5 $(J = 2.8, \text{ CH}_3)$, 26.1 $(J = 64.2, \text{ C}_6)$, 31.7 $(J = 63.4, C_2)$, 37.8 $(J = 63.7, CPh)^6$, 49.9 (CH_3O) , 76.7 ($J = 3.1$, C₃), 121.5 ($J = 7.0$, C₅), 126.5 ($J = 2.0$, $(C_{4'})$, $(127.4 (J = 11.4, C_4), 128.2 (C_{3'})$, $(129.1 (J = 5.0,$ $C_{2'}$),^e 130.7 (*J* = 7.5, $C_{1'}$)^f;¹H NMR (CDCl₃) δ : 1.59 (s, 3H, CH3), 2.00–2.72 (m, 4H, P(CH2)2), 3.21 (d, 2H, *J* $= 15.0$, CH₂Ph), 3.16 (s, 3H, OCH₃),^g 6.06 (bdt, 1H, $J_1 = 23.0, J_2 = 10.0, \text{CH}$, 7.10–7.42 (m, 5H, Ar).

5- and 3-Methyl-1-benzyl-4-chloro-3-hydroxy-1,2,3,6-tetrahydrophosphinine 1-Oxide **6**

A solution of 0.40 g (1.38 mmol) of phosphabicyclohexane oxide **2** consisting of isomers **A** (75%) and **B** (25%) and 2.4 g (13.8 mmol) of silver nitrate in 10 mL of water was refluxed for 2 h. After filtration, the mixture was extracted with chloroform and the organic phase was dried over sodium sulfate and concentrated. The crude product was purified by column chromatography (3% methanol in chloroform, silica gel) to give 0.22 g (60%) of compound **6** as a 5.5:2.4:1.4:1 mixture of four isomers. MS, 271 (100, $[M + H]^+$), 253 (82), 154 (91), 136 (90), 91

[∗] ^A,Bthe corresponding signals within the isomer pairs may be reversed. ^{a−h}tentative assignment.

(92); HRMS, $[M + H]_{\text{found}}^+ = 271.0641$, $C_{13}H_{17}ClO_2P$ requires 271.0655.

6-1. ³¹P NMR (CDCl₃) δ : 37.9; ¹³C NMR (CDCl₃) δ : 23.3 (*J* = 9.6, CH₃), 31.3 (*J* = 64.3, C₆),^a 31.8 $(J = 61.4, C_2)$,^{a†} 36.2 (*J* = 61.6, CPh), 69.5 (C₃), 125.7 $(J = 4.8, C_5)$, 127.2 $(J = 2.9, C_4)$, 128.8 $(J = 2.4, C_5)$ $C_{3'}$), 129.2 (*J* = 5.1, $C_{2'}$), 130.4 (*J* = 8.0, $C_{1'}$), 131.1 $(J = 10.3, C_4)$; ¹H NMR (CDCl₃) δ : 1.92 (s, 3H, CH₃), 2.00–2.65 (m, 4H, P(CH2)2), 3.25 (d, 2H, *J* = 15.0, CH₂Ph), 3.90 (bs, 1H, OH), 4.50 (bd, 1H, $J = 19.0$, CH), 7.10–7.42 (m, 5H, Ar).

6-2. ³¹P NMR (CDCl₃) δ: 35.0; ¹³C NMR (CDCl₃) δ : 23.3 (*J* = 9.6, CH₃), 31.3 (*J* = 64.3, C₆), 32.3 $(J = 61.6, C_2)^b$ 37.0 $(J = 61.9, CPh)$, 69.1 $(J = 4.5,$ C₃), 126.4 ($J = 4.9$, C₅), 126.9 ($J = 3.0$, C₄[']), 128.5 $(J = 2.6, C_{3'})$, 129.7 $(J = 5.3, C_{2'})$, 130.5 $(J = 11.0,$ C₁, 131.3 ($J = 8.8$, C₄); ¹H NMR (CDCl₃) δ : 1.91 (s, 3H, CH₃), 2.00–2.65 (m, 4H, P(CH₂)₂), 3.25 (d, 2H, $J = 15.0$, CH₂Ph), 3.90 (bs, 1H, OH), 4.69 (bd, 1H, *J* = 20.4, CH), 7.10–7.42 (m, 5H, Ar).

6-3. ³¹P NMR (CDCl₃) δ : 35.3; ¹³C NMR (CDCl₃) δ : $26.0 (J = 64.4, C_6)$, $29.5 (J = 5.6, CH_3)$, $30.2 (J = 63.4,$ C₂), 36.4 ($J = 63.2$, CPh), 71.9 ($J = 5.3$, C₃), 118.3 $(J = 6.0, C_5)$, 126.9 $(J = 3.1, C_4)$, 128.6 $(J = 2.9,$ $C_{3'}$), 129.5 (*J* = 5.2, $C_{2'}$), 131.0 (*J* = 8.5, $C_{1'}$), 140.4 $(J = 12.4, C_4)$; ¹H NMR (CDCl₃) δ: 1.63 (s, 3H, CH₃), 2.00–2.65 (m, 4H, $P(CH_2)_2$), 3.25 (d, 2H, $J = 15.0$, CH₂Ph), 3.90 (bs, 1H, OH), 5.84 (bdt, 1H, $J_1 = 24.8$, $J_2 = 4.6$, CH=), 7.10–7.42 (m, 5H, Ar).

6-4: ${}^{31}P$ NMR (CDCl₃) δ : 38.4.

3-Benzyl-3-methyl-1,2,3,4,5,6-hexahydrophosphinine 1-oxide **7** *(from 1-benzyl-4-chloro-3 methyl-1,2-dihydrophosphinine 1-oxide* **4***)*

To 0.30 g (1.19 mmol) of dihydrophosphinine oxide **4** consisting of isomers **A** (75%) and **B** (25%) in 20 mL of ethanol 0.06 g of a 5% Pd–C was added and the mixture was stirred in an autoclave under a 4.5-bar atmosphere of hydrogen at 23◦ C for 24 h. The suspension was filtered, the solvent of the filtrate was evaporated, and the residue purified by column chromatography (2% methanol in chloroform, silica gel) to give 0.21 g (80%) of compound **7** as a 9:1 mixture of diastereoisomers **A** and **B**; MS, 223 (100, [M + H]+), 191 (25), 136 (35), 91 (28); HRMS, $[M + H]_{\text{found}}^+ = 223.1241$, $C_{13}H_{19}OP$ requires 223.1252.

7A. ³¹P NMR (CDCl₃) δ: 39.8; ¹³C NMR (CDCl₃) δ: $22.9 (J = 3.7, C_5)$, $24.2 (J = 15.1, CH_3)$, $26.0 (J = 62.1,$ C₆), 31.7 ($J = 3.6$, C₃), 33.9 ($J = 59.6$, CPh), 34.5 $(J = 5.4, C_4)$, 35.2 $(J = 60.0, C_2)$, 126.8 $(J = 2.8, C_4)$, $128.7 (J = 2.5, C_{3'})$, $129.5 (J = 4.9, C_{2'})$, $131.7 (J = 8.0,$

 $C_{1'}$); ¹H NMR (CDCl₃) δ : 1.04 (dd, 3H, *J* = 6.3, 2.6, CH₃), 1.39–2.22 (m, 9H, $4 \times CH_2 + CH$), 3.17 (d, 2H, $J = 12.6$, CH₂Ph), 7.19–7.41 (m, 5H, Ar).

7B. ³¹P NMR (CDCl₃) δ : **39.9**; ¹³C NMR (CDCl₃) δ : 20.5 ($J = 5.7$, C₅), 24.6 ($J = 14.3$, CH₃), 25.1 ($J = 62.2$, C₆), 28.1 ($J = 4.8$, C₃), 34.2 ($J = 62.4$, CPh), 35.4 $(J = 4.6, C_4)$, 38.8 $(J = 60.0, C_2)$, 128.8 $(J = 2.8, C_4)$, $128.7 (J = 2.5, C_3)$, $129.4 (J = 4.9, C_2)$, $132.0 (J = 7.3,$ $C_{1'}$); ¹H NMR (CDCl₃) δ : 0.98 (dd, 3H, *J* = 6.6, 2.1, CH₃), 1.39–2.22 (m, 9H, $4 \times CH_2$ and CH), 3.14 (d, 2H, $J = 15.5$, CH₂Ph), 7.19–7.41 (m, 5H, Ar).

1-Benzyl-3-methyl-1,2,3,4,5,6-hexahydrophosphinine 1-oxide **7***(from 3-Benzyl-6,6-dichloro-1-methyl-3-phosphabicyclo[3.1.0]hexane 3-oxide* **2***)*

The hydrogenation of phosphabicyclohexane oxide **2** consisting of isomers **A** (75%) and **B** (25%) was performed according to the procedure described above except the mixture was kept under a 9-bar atmosphere of hydrogen at 90◦ C for 16 h. Workup and purification by column chromatography (2% methanol in chloroform, silica gel) afforded 0.11 g (48%) of **7** as a 2:1 mixture of diastereoisomers **A** and **B**.

1-Benzyl-4-chloro-5-methyl-1,2,3,6-tetrahydrophosphinine 1-oxide **8**

To 0.50 g (2.0 mmol) of dihydrophosphinine oxide **4** consisting of isomers **A** (75%) and **B** (25%) in 10 mL of CH_2Cl_2 , 1.5 mL of a 2 M solution of borane–dimethyl sulfide in THF was added and the mixture was stirred for 24 h. The reaction mixture was treated with 0.5 mL of water, stirred for 10 min, and the organic phase was dried over MgSO4. The crude product was purified by column chromatography (3% methanol in chloroform, silica gel) to give 0.36 g (70%) of compound **8** as a 9:1 mixture of two double bond isomers **A** and **B**. HRMS, $[M + H]_{\text{found}}^+$ $= 255.0689$, C₁₃H₁₇ClOP requires 255.0706.

8A. ³¹P NMR (CDCl₃) δ : 34.7; ¹³C NMR (CDCl₃) δ: 23.2 (CH3), 23.6 (*J* = 74.1, C2), 31.2 (d, *J* = 64.1, C_6), 31.4 (*J* = 5,56, C₃), 35.4 (*J* = 63.0, CPh), 124.4 $(J = 5.3, C_4)$, 126.6 $(J = 12.6, C_3)$, 127,1 $(J = 3.1, C_4)$, 128.9 ($J = 2.6$, C_{3'}), 129.4 ($J = 5.2$, C_{2'}), 131.2 ($J = 7.9$, $C_{1'}$); ¹H NMR (CDCl₃) δ: 1.86 (s, 3H, CH₃), 1.85– 2.20 (m, 2H, CH2), 2.28–2.55 (m, 2H, CH2), 2.58–2.80 $(m, 1H, CH₂), 2.80-3.02$ $(m, 1H, CH₂), 3.19$ (dd, 2H, $J = 14.3$, 1.46, CH₂Ph), 7.20–7.40 (m, 5H, Ar). **8B.** ³¹P NMR (CDCl₃) δ : 36.3.

*4- and 6-Methyl-5-chloro-2-oxo-2-benzyl-2*λ5 *phosphabicyclo[2.2.2]octa-5,7-diene-7,8 dicarbonic Acid Dimethyl Ester* **9**

To 60.0 mg (0.24 mmol) of dihydrophosphinine oxide **4** consisting of isomers **A** (75%) and **B** (25%) in

[†] ^a,^b tentative assignment.

3 mL of toluene, 0.15 mL (1.20 mmol) of dimethyl acetylenedicarboxylate was added and the mixture was refluxed for 12 h. The volatiles were evaporated, and the residue was purified by column chromatography (3% methanol in chloroform, silica gel) to give 60.0 mg (66%) of compound **9** as a 37:27:18:18 mixture of four isomers. The spectroscopic data of the four isomers were similar to those published previously (δ_P: (CDCl₃) δ: 55.2, 54.3, 51.0, and 50.0, δ_P lit [13]: 55.3, 54.3, 51.1, and 50.1).

4- and 6-Methyl-2-benzyl-5-chloro-10-phenyl-10-aza-2 λ5*-phosphatricyclo[5.2.2.0*7,8*]undec-5 ene-9,11-dion-2-oxide* **10**

To 60.0 mg (0.24 mmol) of dihydrophosphinine oxide **4** consisting of isomers **A** (75%) and **B** (25%) in 3 mL of toluene, 0.12 g (0.69 mmol) of *N*phenylmaleimide was added and the mixture was refluxed for 8 h. The volatiles were evaporated, and the residue was purified by column chromatography (3% methanol in chloroform, silica gel) to give 50.0 mg (50%) of compound **10** as a 55:45 mixture of diastereomers **A** and **B**. The spectroscopic data of **10A** and **10B** were similar to those published previously (δ_P (CDCl₃) δ: 47.7 and 47.4, δ_P: lit [13] 47.5 and 47.0).

O-Alkyl-benzyl-methylphosphinates **11**

The solution of 40.0 mg (0.10 mmol) of benzylphosphabicyclooctadiene **9** consisting of isomers (37:27:18:18) and 4 mL of the corresponding alcohol in 45 mL of acetonitrile was irradiated in a photochemical reactor with a mercury lamp (125 W) for 1 h. Volatile components were removed, and the residue so obtained was purified by flash chromatography (3% methanol in chloroform, silica gel) to give the corresponding phosphinates **11**.

O-Methyl-benzyl-methylphosphinate **11a***.* Yield: 75%; ³¹P NMR (CDCl₃) δ: 53.5; HRMS, [M + H]⁺_{found} $= 185.0741$, C₉H₁₄O₂P requires 185.0731.

O-Ethyl-benzyl-methylphosphinate **11b** [16]*.* Yield: 75% ; $31P$ NMR (CDCl₃) δ : 51.8; HRMS, $[M + H]_{\text{found}}^+$ $= 199.0871$, $C_{10}H_{16}O_2P$ requires 199.0881.

O-Propyl-benzyl-methylphosphinate **11c***.* Yield: 83% , ³¹P NMR (CDCl₃) δ : 51.3; HRMS, $[M+H]_{\text{found}}^+ = 213.1029,$ $C_{11}H_{18}O_2P$ requires 213.1044.

O-Butyl-benzyl-methylphosphinate **11d***.* Yield: 85% ; $31P$ NMR (CDCl₃) δ : 51.4; HRMS, $[M+H]_{\text{found}}^{+} = 227.1191,$ $C_{12}H_{20}O_{2}P$ requires 227.1201.

REFERENCES

- [1] Phosphorus–Carbon Heterocyclic Chemistry: The Rise of a New Domain; Mathey, F. (Ed.); Pergamon/Elsevier, Amsterdam, 2001.
- [2] Keglevich, Gy. Synthesis 1993, 931.
- [3] Keglevich, Gy. Rev Heteroatom Chem 1996, 14, 119.
- [4] Keglevich, Gy.; Tőke, L. Trends Org Chem 1993, 4, 245.
- [5] Keglevich, Gy. Curr Org Chem 2006, 10, 93.
- [6] Keglevich, Gy.; Szelke, H.; Kovács, J. Curr Org Synth 2004, 1, 377.
- [7] Quin, L. D.; Borleske, S. G.; Engel, J. F. J Org Chem 1973, 38, 1858.
- [8] Buchanan, G. W.; Webb, V. L. Org Magn Reson 1983, 21, 436.
- [9] Sander, M. Chem Ber 1962, 95, 473.
- [10] Kovács, J.; Balázsdi Szabó, N.; Nagy, Z.; Ludányi, K.; Keglevich, Gy. Heteroatom Chem 2005, 16, 320.
- $[11]$ Keglevich, Gy.; Janke, F.; Fülöp, V.; Kálmán, A.; Tóth, G.; Tőke, L. Phosphorus Sulfur 1990, 54, 73.
- [12] Keglevich, Gy.; Tungler, A.; Novák, T.; Tőke, L. J Chem Res (S) 1996, 528.
- [13] Keglevich, Gy.; Steinhauser, K.; Ludányi, K.; Tőke, L. J Organomet Chem 1998, 570, 49.
- [14] Keglevich, Gy.; Dudás, E. Synth Commun (in press).
- [15] Keglevich, Gy.; Kovács, J.; Szelke, H.; Körtvélyesi, T. J Heterocyclic Chem 2006, 43, 723.
- [16] Steininger, E. Chem Ber 1963, 96, 3184.